The Dental and Pharmaceutical Benefits Agency, TLV
Jonas Samuelsson is an experienced analyst currently working at The Dental and Pharmaceutical Benefits Agency (TLV) since November 2022, focusing on data extraction, analysis, and report writing using R, SQL, and Python. Previously, Jonas served as a Research Assistant at Karolinska Institutet, managing and analyzing data for international projects related to perinatal health and mental well-being during the COVID-19 pandemic. Jonas also held positions at the European Centre for Disease Prevention and Control as an Interim Project Officer, conducting biostatistics and data analysis, and interned at various organizations, including SCB and the United Nations Economic Commission for Europe, where data analysis and report writing were key responsibilities. Educational qualifications include a Master of Science in Demography from Stockholm University and a Bachelor of Arts in International Relations from Corvinus University of Budapest.
The Dental and Pharmaceutical Benefits Agency, TLV
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidized by the state. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society. We also contribute to quality service and accessibility of pharmacies. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society.In addition to examining new medicines, we also work systematically to evaluate the medicines included in the high-cost threshold to determine whether their reimbursement should be maintained or restricted. On the pharmacy market our remit is to create the conditions for quality service and accessibility at pharmacies. We do this partly through the generic substitution system, the retail margin for pharmacies and by monitoring the pharmacy market. Furthermore, we decide how much a medicine or a medical device in the high-cost threshold should cost. And, we determine what margin pharmacies should use when selling products, meaning the difference between the wholesale and retail prices. We determine the pricing for new dosage forms, strengths and packaging and examine whether they should be included in the high-cost threshold.